Foghorn Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FHTX research report →
Range $9 – $20
Price Chart
About the company
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system.
- CEO
- Adrian H. Gottschalk
- IPO
- 2020
- Employees
- 106
- HQ
- Watertown, MA, US
Get TickerSpark's AI analysis on FHTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $411.58M
- P/E
- -7.08
- Fwd P/E
- 42.92
- PEG
- -0.40
- P/S
- 11.20
- P/B
- -6.11
- EV/EBITDA
- -6.19
- Div Yield
- 0.00%
- Gross Margin
- 42.73%
- Op Margin
- -186.38%
- Net Margin
- -175.78%
- ROE
- 72.64%
- ROIC
- -44.00%
Latest fiscal year · YoY change
- Revenue
- $30.91M+36.8%
- Gross Profit
- $27.58M+22.0%
- Op Income
- $-82,107,000
- Net Income
- $-74,283,000+14.2%
- EPS
- $-1.18+25.3%
- OCF Growth
- +14.2%
- FCF Growth
- +15.0%
- 52W High
- $7.61
- 52W Low
- $3.27
- 50D MA
- $5.15
- 200D MA
- $5.00
- Beta
- 2.83
- RSI (14)
- 71
- Avg Volume
- 265.52K
No earnings-call transcripts are available for FHTX yet.
- Free Float
- 46.7%
- Shares Outstanding
- 58.71M
- Float Shares
- 27.41M
of shares held by institutions
93 13F filers
Buy/sell ratio 5.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 1.93M | ▲ 29.54K |
| Two Sigma Advisers, LP | 10.40K | ▲ 10.40K |
| Evelyn Partners Asset Management Ltd | 7.10K | 0 |
| Cwm, LLC | 3.35K | ▲ 2.00K |
| California State Teachers Retirement System | 1.80K | ▼ 247 |
| Sunbelt Securities, Inc. | 1.00K | 0 |
Held by 89 ETFs
Biggest fund positions in FHTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 24, 26 | Lynch Thomas J. Jr. | other | 28,000 |
| Jun 24, 26 | Duty Stuart | other | 28,000 |
| Jun 24, 26 | Biller Scott | other | 28,000 |
| Jun 24, 26 | Gallagher Neil | other | 28,000 |
| Jun 24, 26 | Mendelsohn Michael | other | 28,000 |
| Jun 24, 26 | SMITH IAN F | other | 28,000 |
| Jun 24, 26 | GILL SIMBA | other | 28,000 |
| Jun 24, 26 | PARSHALL B LYNNE | other | 28,000 |
| Jun 24, 26 | Cole Douglas G. | other | 28,000 |
| Apr 10, 26 | GOTTSCHALK ADRIAN | other | 59,208 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FHTX coverage
Recent articles, reports, and earnings notes.
No research on FHTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FHTX report →Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy
zacks.com · Aug 14
Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 88.47%: Here's is How to Trade
zacks.com · Aug 10
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Beats Revenue Estimates
zacks.com · Aug 6
Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update
globenewswire.com · Aug 6
Reviewing Foghorn Therapeutics (NASDAQ:FHTX) and Sunshine Biopharma (NASDAQ:SBFM)
defenseworld.net · Jul 30
Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains?
zacks.com · Jul 3
Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director
globenewswire.com · Jul 1
Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director
globenewswire.com · Jul 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.